A comparison of the reactivity and immunogenicity of RA 27/3 strain rubella vaccine prepared in WI-38 or MRC5 human diploid cells |
| |
| Authors: | H Zealley E Edmond J M Inglis W M Shepherd D T Langford |
| |
| Affiliation: | 1. Lothian Health Board, Edinburgh, Scotland;2. Department of Bacteriology, University of Edinburgh Medical School, Edinburgh, Scotland;3. Regional Virus Laboratory, City Hospital, Edinburgh, Scotland;4. Clinical and Applied Research Division, Wellcome Research Laboratories, Beckenham, Kent, UK;1. Halozyme Therapeutics, Clinical Development and Translational Medicine, 11388 Sorrento Valley Road, San Diego, CA 92121, United States;2. The Westmead Institute for Medical Research, University of Sydney, Australia;3. Departments of Pedatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States;1. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA;2. Novavax, Inc., Gaithersburg, MD, USA;4. Department of Molecular Virology and Microbiology and Pediatrics, Baylor College of Medicine, Houston, TX, USA;1. State Key Laboratory of Clean Energy Utilization, Zhejiang University, Hangzhou 310027, China;2. School of Energy and Power Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China |
| |
| Abstract: | The immunogenicity and clinical reactivity of rubella vaccine derived from WI-38 or MRC5 human diploid cells was compared in 125 seronegative adolescent females. Seroconversion rates, assessed by single radial haemolysis testing of paired pre- and post-vaccination samples exceeded 98% (56/57 and 68/68 vaccinees, respectively) for both vaccines. Quantitative assessment of rubella-specific antibodies in 53 post-vaccination sera by an ELISA technique also failed to reveal any difference in immunogenicity between the vaccines. Assessable calendar records documenting the occurrence of local and systemic signs and symptoms in the four weeks following vaccination were returned by 106 subjects. No important statistically significant difference in parameters of clinical reactivity between the vaccine groups was observed although the incidence of pain at the injection site was found to be significantly higher for vaccinees receiving WI-38 derived vaccine. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
